#37: Description of Moderate-Severe Cases of COVID-19 in Pediatric Cancer at the Unidad Nacional de Oncologia Pediatrica, Guatemala
| Autor: | Alicia Chang Cojulun, Federico Antillón Klussmann, Thelma Beatriz Velásquez Herrera, Susana María Godoy Escobar, Mario Augusto Melgar Toledo, Roy Enrique Rosado |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
education.field_of_study Palliative care Global Health Research business.industry Population General Medicine Disease Neutropenia medicine.disease Pediatric cancer Asymptomatic Leukemia Abstracts Infectious Diseases AcademicSubjects/MED00290 Intensive care Internal medicine Pediatrics Perinatology and Child Health medicine medicine.symptom business education AcademicSubjects/MED00670 |
| Zdroj: | Journal of the Pediatric Infectious Diseases Society |
| ISSN: | 2048-7207 2048-7193 |
| Popis: | Introduction Guatemala reported the first confirmed SARS-CoV-2 case on March 13th 2020. Up to now, more than 140,000 confirmed cases have been documented, with 8% of them being Methods This is a descriptive, prospective report of pediatric cancer patients Results Two hundred one patients with pediatric cancer with the SARS-CoV-2 infection were confirmed. Sixty four percent were male (n=128), median of age was 9.5 years (5-m to 18-y). The primary oncologic diagnosis was leukemia 65% (n=129), and other solid tumors 35% (n=72), 5% (n=10) of patients were in palliative care. In leukemia patients, 40% were receiving induction therapy (n=51), 25% consolidation (n=32), and 19% maintenance (n=25). The most common initial symptom was fever in 32% (n=64) and 33% were asymptomatic (n=67). Twenty two percent developed moderate disease (n=44) and 13% severe disease (n=26). A total of 13 patients died during COVID-19 period (6%) and 7 of them died receiving active treatment (3%). The risk of developing moderate-severe disease was not higher in leukemia patients compared to patients with other tumors who were receiving intense chemotherapy (OR=0.7), but there might be a higher risk of death (OR=1.41). In patients with leukemia, the risk of developing moderate-severe disease was higher for patients receiving induction therapy compared with those in consolidation (OR=6.7) or maintenance (OR=3.04). Mortality risk seems to be higher in patients with leukemia during induction therapy (OR=1.94). Confirmed coinfections correlated with higher risk of severe illness (OR=1.95) and death during the COVID-19 period (OR=5.2). Conclusions The mortality due to COVID-19 in pediatric cancer is low and could be related to coinfections or intensive chemotherapy. Important limitation of our report is the lack of analysis of underlying clinical conditions in moderate-severe disease (neutropenia or other comorbidities), factors that could have an impact on our data analysis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|